Patents by Inventor John S. Kovach

John S. Kovach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180244690
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Patent number: 10023587
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: July 17, 2018
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S Kovach, Francis Johnson
  • Patent number: 9988394
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 5, 2018
    Assignee: Lixte Biotechnology Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Publication number: 20170369503
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 28, 2017
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S KOVACH, Francis JOHNSON
  • Patent number: 9833450
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: December 5, 2017
    Assignees: LIXTE BIOTECHNOLOGY, INC., INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: John S Kovach, Salvatore Lecca, Manuel Mameli
  • Publication number: 20170340628
    Abstract: Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: July 23, 2015
    Publication date: November 30, 2017
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Publication number: 20170259081
    Abstract: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.
    Type: Application
    Filed: December 20, 2016
    Publication date: September 14, 2017
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventor: John S. Kovach
  • Publication number: 20170240558
    Abstract: Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.
    Type: Application
    Filed: May 8, 2017
    Publication date: August 24, 2017
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. KOVACH, Francis JOHNSON, Ramakrishna SAMUDRALA
  • Publication number: 20170136008
    Abstract: A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of a compound having the structure:
    Type: Application
    Filed: June 19, 2015
    Publication date: May 18, 2017
    Applicants: Lixte Biotechnology, Inc., The United States of America, as Represented by th e Secretary, Department of Health & Human Service
    Inventors: John S. Kovach, Zhengping Zhuang, Ki-eun Chang, Matthew Hall, Michael M. Gottesman
  • Patent number: 9526915
    Abstract: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: December 27, 2016
    Inventor: John S. Kovach
  • Publication number: 20160333024
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: May 13, 2016
    Publication date: November 17, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventors: JOHN S. KOVACH, ROBERT VOLKMANN, ANTHONY MARFAT
  • Publication number: 20160303115
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Application
    Filed: February 19, 2016
    Publication date: October 20, 2016
    Applicants: Lixte Biotechnology, Inc., Institut national de la santé et de la recherche médicale
    Inventors: JOHN S. KOVACH, SALVATORE LECCA, MANUEL MAMELI
  • Publication number: 20160264593
    Abstract: The present invention provides a method for in vivo delivery of endothal to a target cell in a subject, the method comprising administering to the subject a compound having the structure: Formula (I).
    Type: Application
    Filed: November 14, 2014
    Publication date: September 15, 2016
    Inventors: John S. Kovach, Francis Johnson, Ramakrishna Samudrala, Ramesh C. Gupta
  • Publication number: 20160074390
    Abstract: The present invention provides a method of inhibiting protein phosphatase 2A (PP2A) in a human subject in need thereof comprising administering to the subject an amount of from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure or a salt, zwitterion, or ester thereof, so as to thereby inhibit protein phosphatase 2A (PP2A) in the subject.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventor: JOHN S. KOVACH
  • Publication number: 20160051544
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Application
    Filed: April 8, 2014
    Publication date: February 25, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. KOVACH, Mickey L. WELLS
  • Publication number: 20160009727
    Abstract: Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. KOVACH, Francis JOHNSON, Ramakrishna SAMUDRALA
  • Publication number: 20160008336
    Abstract: The present invention provides a method of treating a subject suffering from traumatic brain injury comprising administering to the subject an effective amount of an HDAC inhibitor, structurally represented, thereby treating the subject suffering from traumatic brain injury.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventor: John S. KOVACH
  • Patent number: 9079917
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: July 14, 2015
    Assignee: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S. Kovach, Francis Johnson
  • Publication number: 20150174123
    Abstract: A method of reducing reperfusion injury in mammalian tissue comprising contacting the tissue with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Application
    Filed: June 28, 2013
    Publication date: June 25, 2015
    Applicant: Lixte Biotechnology, Inc.
    Inventor: John S. Kovach
  • Publication number: 20150148353
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Application
    Filed: June 28, 2013
    Publication date: May 28, 2015
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventor: John S. Kovach